Immunological system – no discrete molecular drug target

The classification 'Immunological system – no discrete molecular drug target' is used in pharmacological resources, such as the IUPHAR/BPS Guide to Pharmacology, to describe agents that modulate the immune system through broad, systemic mechanisms rather than by binding to a specific molecular target like a receptor or enzyme (IUPHAR/BPS, 2024). This category encompasses a variety of therapeutic interventions, including vaccines like the BCG vaccine and immunomodulators like glatiramer acetate, which influence multiple immune cell types and signaling networks simultaneously (PubMed, PMID: 25637281). Instead of a specific molecular interaction, these drugs produce a therapeutic effect by altering the overall immune environment, such as shifting cytokine production or modifying leukocyte recruitment (StatPearls, 2023). Such systemic modulation is particularly useful in treating complex diseases like multiple sclerosis and certain types of cancer where a multi-pronged immune response is required (NIH, 2022). However, the lack of a discrete target can lead to challenges in predicting drug behavior and managing safety, as the effects are often widespread and can include risks like cytokine release syndrome or unintended immunosuppression (Journal of Clinical Investigation, 2021). This entry serves as a functional placeholder for drugs whose clinical efficacy is well-established but whose molecular "target" is the integrated immune system itself.

Other names

Immune systemNon-specific immunomodulationSystemic immune responseNon-specific immunological target

Systemic modulation of immune cell activity and cytokine signaling pathways without a defined interaction with a single molecular receptor or enzyme (IUPHAR/BPS Guide to Pharmacology).